Replies to post #817876 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Jesster, I believe all the proof you need should come from Posner's taking a spoofing suit on contingency against the 7 largest MM's for NWBO. She's one of the top litigators in this field, if it goes to full discovery, and she can expose their action all the way to the present, I'm sure it will show just how hard they're working. I don't know that it will happen, they may settle sooner, or the court may limit how far they can look, but I believe that the more they see, the more they'll be permitted to see. Even if they're not permitted to go beyond what occurred at the time of the NYAS presentation, I believe the award will be substantial.

The point is, the 7 MM's can facilitate naked shorting by clients through derivatives that can't be seen. If those clients are smart they've been closing these positions while the stock's down, but I still believe a large naked position may exist. We should get a substantial squeeze on approval, how high we spike to may be caused by the squeeze, but will largely be dependent on how much media attention we get with the news of the approval.

I honestly don't understand derivatives and other maneuvers the MM's, hedge funds, etc. can facilitate. I wish investing was simply looking for companies that would succeed and investing in them, but investing has gone far beyond that. Hedge fund managers who made billions for their clients by bringing companies down have earned billions of dollars in bonuses themselves based on the money they've made for their clients. In 2008 they virtually brought down the economy and took some of the biggest companies into bankruptcy, the likes of Lehman Bros, WaMu, etc. are no longer with us because of how things were done back then, and most of it's still legal today.

Frankly, if we do hit peaks at $10 or more, I'd be willing to bet that shorts who may have big losses on the approval announcement are right back in their short positions at least for the retrenching that undoubtably will occur after such a peak. I don't know if they'll recover all their losses, but recovering some of it is practically certain. I believe if they're smart they get out on retrenching as more news can bring new highs.

Gary

[HyGro]

Not that simple. UK is a lousy oncology market, only 1/10th the size of the U.S. And the UK payers are loath to pay for very pricey personalized oncology treatments. CAR-T, a very successful blood cancer treatment, took over 5 years to get any UK government reimbursement, only from the NICE charity for a very limited number of patients. So even if DCVax-L gets approved, the access to patients is very likely to be very limited. This makes it very challenging for NWBO to make a a profit -- compassionate care at cost of goods likely. That leaves NWBO very challenged to survive for more than a few years.

U.S. FDA has clearly already told NWBO they won't accept their P3 trial and will require another onerous trial that will take years again.

This is not a very positive scenario and one that is likely if MHRA approves DCVax-L. If not, NWBO falls back on being the Advent contract manufacturer.

[acelerator]

Looks like Gary answered your question for me. Should you have further questions, contact Laura Posner.

[AllSheWrote]

This company has been around for more than 25 years and to this day has just above zero revenue. They have stayed in business by diluting into the billions of shares. That's their business model. They have no product and it's obvious DCVax is a failure and will never be approved for commercial distribution anywhere. Some people will continue hanging on to this stock until it dwindles below one penny, or until they die, whichever comes first. Some of them have already started dropping off. I have no sympathy for such ignorance when the plain truth could not be more obvious.